DPYD, dihydropyrimidine dehydrogenase, 1806

N. diseases: 249; N. variants: 101
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.360 Biomarker disease BEFREE Moreover, we have established that increasing the length of the alkyl chain at the quaternised nitrogen of the 4-(<i>N</i>-alkylpyridinium)-1,4-DHP molecule or the introduction of propargyl moieties in the 1,4-DHP molecule significantly influences the cytotoxicity on HT-1080 (human fibrosarcoma) and MH-22A (mouse hepatocarcinoma) cell lines, as well as the estimated basal cytotoxicity. 30871041 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.360 Biomarker disease BEFREE Mechanistically, DPYD functioned as a positive regulator of EMT in HCC by targeting the p38/NF-κB/Snail1 pathway. 29358721 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.360 AlteredExpression disease BEFREE Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1. 28693254 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.360 Biomarker disease BEFREE We examined two genetic polymorphisms of the metabolic enzymes cytochrome P450 2A6 (CYP2A6) and dihydropyrimidine dehydrogenase (DPD) in 58 Japanese hepatitis C virus-seropositive HCC patients. 23571497 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.360 Biomarker disease BEFREE Sorafenib and S-1 (one mixed formulation containing 5-FU prodrug and dihydropyrimidine dehydrogenase inhibitor) were two effective agents against hepatocellular carcinoma (HCC), but whether they had synergistic effects remained unclear. 23435877 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.360 Biomarker disease CTD_human The DPD mRNA level in HCC (4.31 +/- 4.21) was lower than that in adjacent liver (6.53 +/- 2.93) (p < 0.001). 18019677 2007
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.360 Biomarker disease BEFREE This study examines the role of DPD in the antiproliferative effects of 5-FU combined with IFN-alpha on hepatocellular carcinoma (HCC) cells in culture and asks whether IFN-alpha could affect DPD expression. 17699726 2007